tert-butyl N-[4-morpholino-6-(2-tetrahydropyranyloxymethyl)-2-pyridyl]carbamate | 196499-66-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: tert-butyl N-[4-morpholino-6-(2-tetrahydropyranyloxymethyl)-2-pyridyl]carbamate
• 英文别名: {4-(morpholin-4-yl)-6-[(tetrahydro-2H-pyran-2-yloxy)methyl]pyridin-2-yl}carbamic acid tert-butyl ester；{4-(4-morpholinyl)-6-[(tetrahydro-2H-pyran-2-yloxy)methyl]-2-pyridinyl}carbamic acid tert-butyl ester；tert-butyl N-[4-morpholin-4-yl-6-(oxan-2-yloxymethyl)pyridin-2-yl]carbamate
• CAS: 196499-66-8
• 化学式: C₂₀H₃₁N₃O₅
• 分子量: 393.483
• InChiKey: ZVBSRJNCEBBEKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  82.2
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  tert-butyl N-[4-morpholino-6-(2-tetrahydropyranyloxymethyl)-2-pyridyl]carbamate 在 对甲苯磺酸 作用下， 以 乙醇 为溶剂， 生成 tert-butyl N-(6-hydroxymethyl-4-morpholino-pyridin-2-yl)carbamate
  参考文献：
  名称：

  Synthesis and evaluation of a series of 2,4-diaminopyridine derivatives as potential positron emission tomography tracers for neuropeptide Y Y1 receptors

  摘要：

  A series of 2,4-diaminopyridine derivatives was synthesized and evaluated as potential candidates for neuropeptide Y (NPY) Y1 receptor positron emission tomography (PET) tracers. Derivatives bearing substitutions allowing reliable access to radiolabeling were designed, focusing on Y1 binding affinity and lipophilicity. The advanced derivatives 2n and 2o were identified as promising PET tracer candidates. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.07.030
• 作为产物：
  描述：

  吗啉 、 2-[(tert-butoxycarbonyl)amino]-6-[(tetrahydro-2H-pyran-2-yloxy)methyl]pyridin-4-yl trifluoromethanesulfonic acid 以 二甲基亚砜 为溶剂， 反应 21.0h， 生成 tert-butyl N-[4-morpholino-6-(2-tetrahydropyranyloxymethyl)-2-pyridyl]carbamate
  参考文献：
  名称：

  [EN] HETEROARYLTHIOMETHYL PYRIDINE DERIVATIVE
  [FR] DÉRIVÉ D'HÉTÉROARYLTHIOMÉTHYL PYRIDINE

  摘要：

  本发明涉及一种由以下公式（I）表示的化合物：其中X是由表示的基团或类似的基团；Y是由表示的基团或类似的基团；Ar1是由表示的基团或其药用可接受盐。

  公开号：

  WO2010126163A1

文献信息

• HETEROARYLTHIOMETHYL PYRIDINE DERIVATIVE
  申请人：Kameda Minoru

  公开号：US20120028970A1

  公开（公告）日：2012-02-02

  The present invention relates to a compound represented by a formula (I): wherein X is a group represented by or the like; Y is a group represented by or the like; and Ar 1 is a group represented by or a pharmaceutically acceptable salt thereof.

  本发明涉及一种由式(I)表示的化合物：其中X是由等表示的基团；Y是由等表示的基团；Ar1是由等表示的基团或其药学上可接受的盐。
• ALKYLAMINOPYRIDINE DERIVATIVE
  申请人：Ando Makoto

  公开号：US20110015181A1

  公开（公告）日：2011-01-20

  The present invention relates to a compound that is useful for treatment of, for example, hypertension, arteriosclerosis, bulimia and obesity because of having an antagonistic action to a neuropeptide Y receptor and is represented by formula (I) [wherein R 1 represents hydrogen, cyano, or the like; R represents a group represented by formula (II); X 1 represents C 1-4 lower alkylene or the like; X 2 represents lower alkylene or the like; and Het represents a 5-membered heteroaromatic ring that has at least one nitrogen atom and, in addition, one or two hetero atoms selected from the group consisting of nitrogen, sulfur and oxygen atoms] or to a pharmaceutically acceptable salt thereof.

  本发明涉及一种化合物，由式(I)表示，该化合物具有对神经肽Y受体的拮抗作用，因此可用于治疗高血压、动脉硬化、暴食症和肥胖症等疾病。其中，R1代表氢、氰或类似物；R代表由式(II)表示的基团；X1代表C1-4低烷基或类似物；X2代表低烷基或类似物；Het代表一个五元杂环芳香环，其中至少有一个氮原子，并且还有一个或两个来自氮、硫和氧原子组成的杂原子。该化合物或其药学上可接受的盐可用于治疗上述疾病。
• AMINOPYRIDINE DERIVATIVES
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP0889034A1

  公开（公告）日：1999-01-07

  The present invention relates to a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, and a treating agent for hyperphagia, obesity or diabetes, which comprises such a compound or salt as an active ingredient: [wherein Ar1 is an aryl group or an aromatic heterocyclic group, which may be substituted by a group selected from the group consisting of a lower alkyl group, a lower hydroxyalkyl group, a lower alkylene group and a group represented by -NRaRb; R1 is a hydrogen atom or a lower alkyl group; each of R2 and R3 which are the same or different, is a lower alkyl group, or both of R2 and R3 are bonded to each other to form an alkylene group which may have an oxygen atom or a sulfur atom interposed, said alkylene group being a group which may be substituted by one or two lower alkyl groups; R4 is a hydrogen atom, or a lower alkyl group which may be substituted by a group selected from the group consisting of a hydroxyl group, an amino group, a carbamoyl group and a lower alkoxycarbonyl group; Ar2 is an aryl group or an aromatic heterocyclic group, which may be substituted by a group selected from the group consisting of a halogen atom, a hydroxyl group, a lower alkyl group, a lower haloalkyl group, a lower alkoxy group, a lower alkylthio group, a lower hydroxyalkyl group, a lower alkoxy-lower alkyl group, a group represented by -NRcRd and a group represented by -NRe-CO-NRfRg; W is an oxygen atom, a sulfur atom, or a group represented by -CHRj- or -NRk-].

  本发明涉及一种通式(I)代表的化合物或其药学上可接受的盐，以及一种治疗食欲亢进、肥胖或糖尿病的药物，其有效成分包括这样的化合物或盐： [其中 Ar1 是芳基或芳香杂环基，可被选自由低级烷基、低级羟烷基、低级亚烷基和 -NRaRb 所代表的基团组成的基团取代；R1 是氢原子或低级烷基；相同或不同的 R2 和 R3 中的每一个都是低级烷基，或 R2 和 R3 两者相互键合形成一个亚烷基，该亚烷基中可能有一个氧原子或一个硫原子，所述亚烷基是一个可被一个或两个低级烷基取代的基团；R4 是氢原子，或可被选自羟基、氨基、氨基甲酰基和低级烷氧基羰基的基团取代的低级烷基；Ar2 是芳基或芳香杂环基，可被选自由卤素原子、羟基、低级烷基、低级卤代 烷基、低级烷氧基、低级烷硫基、低级羟烷基、低级烷氧基-低级烷基、由 -NRcRd 表示的基团和由 -NRe-CO-NRfRg 表示的基团组成的组取代；W 是氧原子、硫原子或由 -CHRj- 或 -NRk- 代表的基团]。
• EP2264026
  申请人：——

  公开号：——

  公开（公告）日：——
• Optimization of a series of 2,4-diaminopyridines as neuropeptide Y Y1 receptor antagonists with reduced hERG activity
  作者：Minoru Kameda、Kensuke Kobayashi、Hirokatsu Ito、Hiroshi Miyazoe、Toshiaki Tsujino、Chisato Nakama、Hiroshi Kawamoto、Makoto Ando、Sayaka Ito、Tomoki Suzuki、Tetsuya Kanno、Takeshi Tanaka、Yoshio Tahara、Takeshi Tani、Sachiko Tanaka、Shigeru Tokita、Nagaaki Sato

  DOI：10.1016/j.bmcl.2009.05.069

  日期：2009.8

  The synthesis and evaluation of a series of 2,4-diaminopyridine-based neuropeptide Y Y1 ( NPY Y1) receptor antagonists are described. Compound 1 was previously reported by our laboratory to be a potent and selective Y1 antagonist; however, 1 was also found to have potent hERG inhibitory activity. The main focus of this communication is structure-activity relationship development aimed at eliminating the hERG activity of 1. This resulted in the identification of compound 3d as a potent and selective NPY Y1 antagonist with reduced hERG liability. (C) 2009 Elsevier Ltd. All rights reserved.